A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Summary

An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic Congenital adrenal hyperplasia (CAH) subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.

Timeline

Start

2021-02-22

Primary completion

2024-10-31

Completion

2025-01-31

Outcome

Missed primary endpoint

Stopped: “Study did not meet its primary endpoint.”

release “CAHmelia-204 Study of 200mg Once-Daily ( QD) Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Did Not Achieve Primary Endpoint of Glucocorticoid (GC) Reduction” sprucebio.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tildacerfont	Small molecule	—	Oral

Indications